Afimetoran

Generic Name: Afimetoran

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₂N_₆O

CAS Number: 2171019-55-7

Unique Ingredient Identifier: LXP7MZL0VF

Background: Afimetoran is an immunomodulator and an antagonist of toll-like receptors 7 and 8. It is also is under investigation in clinical trial NCT04269356 (Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of Midazolam

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Afimetoran
Drug: Midazolam
Drug: Phenytoin

First Posted Date: 2023-06-13

Last Posted Date: 2024-08-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 65

Registration Number: NCT05901714

Locations: 🇺🇸
Local Institution - 0001, Miami, Florida, United States

A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants

Phase 1

Recruiting

Conditions: Healthy Volunteers

Interventions: Drug: Famotidine
Drug: Afimetoran

First Posted Date: 2023-05-19

Last Posted Date: 2024-01-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 76

Registration Number: NCT05866627

Locations: 🇬🇧
Quotient Sciences, Nottingham, United Kingdom

A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986256
Drug: Famotidine

First Posted Date: 2021-06-28

Last Posted Date: 2022-01-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 22

Registration Number: NCT04941755

Locations: 🇺🇸
PPD Development, LP, Austin, Texas, United States

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

Phase 2

Recruiting

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Afimetoran
Other: Placebo

First Posted Date: 2021-05-20

Last Posted Date: 2024-11-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 268

Registration Number: NCT04895696

Locations: 🇺🇸
Local Institution - 0137, South Miami, Florida, United States
🇺🇸
Bay Area Arthritis and Osteoporosis, Brandon, Florida, United States
🇺🇸
Clinical Research of West Florida, Inc. (Clearwater), Clearwater, Florida, United States

and more 170 locations

A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus

Phase 1

Completed

Conditions: Lupus Erythematosus, Cutaneous

Interventions: Drug: BMS-986256
Other: BMS-986256 Placebo

First Posted Date: 2020-07-30

Last Posted Date: 2023-05-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 13

Registration Number: NCT04493541

Locations: 🇩🇪
Local Institution - 0001, Berlin, Germany

Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986256
Drug: Famotidine

First Posted Date: 2020-07-14

Last Posted Date: 2022-01-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 35

Registration Number: NCT04470778

Locations: 🇺🇸
ICON (PRA Health Sciences) - Salt Lake, Salt Lake City, Utah, United States

Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986256
Drug: Milk of magnesia

First Posted Date: 2020-02-13

Last Posted Date: 2022-01-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 8

Registration Number: NCT04269356

Locations: 🇺🇸
Covance - Clinical Pharmacology Services - Madison, Madison, Wisconsin, United States

Effects of BMS-986256 at Steady State on the Single Dose Pharmacokinetics of Mycophenolate Mofetil

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986256
Drug: Mycophenolate Mofetil

First Posted Date: 2019-07-31

Last Posted Date: 2020-06-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 15

Registration Number: NCT04039373

Locations: 🇺🇸
PRA Health Sciences - Salt Lake, Salt Lake City, Utah, United States

A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986256
Drug: Loestrin

First Posted Date: 2019-07-11

Last Posted Date: 2022-05-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 32

Registration Number: NCT04016753

Locations: 🇺🇸
Altasciences Los Angeles (Formerly WCCT Global), Cypress, California, United States

A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of BMS-986256 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986256
Drug: Itraconazole

First Posted Date: 2019-05-15

Last Posted Date: 2020-02-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 15

Registration Number: NCT03950960

Locations: 🇺🇸
PRA Health Sciences - Lenexa, Lenexa, Kansas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy